Teva Settles Mississippi Allegations Of Price-Fixing Collusion In The Generic Drugs Market

Bernard Nash
Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • Mississippi AG Lynn Finch reached a settlement with Teva Pharmaceuticals USA, Inc. (“Teva”) to resolve allegations of price fixing and market allocation for numerous generic drugs in violation of the Sherman Act.
  • The settlement stems from a 2019 complaint by 43 state AGs, and the Puerto Rico AG, against Teva and more than a dozen rivals, as well as related individual pharmaceutical executives, alleging that they colluded to divide the generic pharmaceutical customer base to artificially inflate prices in a coordinated manner for drugs used to treat numerous conditions, including multiple sclerosis, HIV, ADHD, kidney disease, and cancer, among other things.
  • Under the terms of the settlement, Teva will pay $925,000 to Mississippi for the voluntary dismissal of Mississippi’s claims in the 2019 case and other related cases.

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide